Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CSTL NASDAQ:PSNL NASDAQ:RDNT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSTLCastle Biosciences$24.30+6.1%$21.60$14.59▼$44.28$737.02M1.04328,777 shs1.04 million shsPSNLPersonalis$13.02+3.4%$8.42$3.84▼$13.37$1.36B2.283.22 million shs8.35 million shsRDNTRadNet$60.74+1.2%$55.96$50.76▼$85.84$4.78B1.41866,020 shs2.98 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSTLCastle Biosciences0.00%+15.06%+9.91%+3.27%+24.81%PSNLPersonalis0.00%+23.53%+18.58%+105.36%+115.92%RDNTRadNet0.00%+13.03%+9.82%+8.17%+8.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSTLCastle Biosciences$24.30+6.1%$21.60$14.59▼$44.28$737.02M1.04328,777 shs1.04 million shsPSNLPersonalis$13.02+3.4%$8.42$3.84▼$13.37$1.36B2.283.22 million shs8.35 million shsRDNTRadNet$60.74+1.2%$55.96$50.76▼$85.84$4.78B1.41866,020 shs2.98 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSTLCastle Biosciences0.00%+15.06%+9.91%+3.27%+24.81%PSNLPersonalis0.00%+23.53%+18.58%+105.36%+115.92%RDNTRadNet0.00%+13.03%+9.82%+8.17%+8.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCSTLCastle Biosciences 2.80Moderate Buy$42.4374.60% UpsidePSNLPersonalis 2.57Moderate Buy$11.00-15.51% DownsideRDNTRadNet 2.90Moderate Buy$87.4343.94% UpsideCurrent Analyst Ratings BreakdownLatest PSNL, CSTL, and RDNT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026CSTLCastle Biosciences Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.006/24/2026CSTLCastle Biosciences Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/1/2026CSTLCastle Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/29/2026CSTLCastle Biosciences KeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$35.005/26/2026CSTLCastle Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/20/2026RDNTRadNet BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$70.00 ➝ $65.005/13/2026CSTLCastle Biosciences BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $40.005/12/2026RDNTRadNet Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/12/2026PSNLPersonalis Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$10.00 ➝ $9.005/11/2026PSNLPersonalis BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$13.00 ➝ $11.005/7/2026CSTLCastle Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)(Data available from 6/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCSTLCastle Biosciences$344.23M2.14$1.11 per share21.83$16.13 per share1.51PSNLPersonalis$69.65M19.58N/AN/A$2.94 per share4.43RDNTRadNet$2.04B2.34$3.22 per share18.84$17.58 per share3.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCSTLCastle Biosciences-$24.16M-$0.44N/AN/AN/A-3.78%-2.77%-2.30%8/3/2026 (Estimated)PSNLPersonalis-$81.27M-$1.02N/AN/AN/A-148.11%-43.52%-32.92%8/4/2026 (Estimated)RDNTRadNet-$18.65M-$0.18N/A60.74N/A-0.66%2.77%0.97%8/10/2026 (Estimated)Latest PSNL, CSTL, and RDNT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026RDNTRadNet-$0.14-$0.28-$0.14-$0.43$557.93 million$575.63 million5/7/2026Q1 2026PSNLPersonalis-$0.23-$0.29-$0.06-$0.29$14.49 million$15.47 million5/6/2026Q1 2026CSTLCastle Biosciences-$0.49-$0.49N/A-$0.49$79.23 million$84.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCSTLCastle BiosciencesN/AN/AN/AN/AN/APSNLPersonalisN/AN/AN/AN/AN/ARDNTRadNetN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCSTLCastle Biosciences0.026.756.53PSNLPersonalisN/A6.616.44RDNTRadNet0.791.171.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCSTLCastle Biosciences92.60%PSNLPersonalis61.91%RDNTRadNet77.90%Insider OwnershipCompanyInsider OwnershipCSTLCastle Biosciences6.10%PSNLPersonalis4.20%RDNTRadNet5.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCSTLCastle Biosciences54030.33 million28.48 millionOptionablePSNLPersonalis400104.72 million100.32 millionOptionableRDNTRadNet11,26478.63 million74.23 millionOptionableRDNT, PSNL, and CSTL HeadlinesRecent News About These CompaniesRDNT Stock Price PredictionJune 25 at 1:33 PM | 247wallst.comDeepHealth Receives FDA Clearances for New BAC Assessment and Prior Exam Integration in Breast SuiteJune 25 at 6:31 AM | quiverquant.comQDeepHealth Receives Two FDA Clearances Enabling it to Add Cardiovascular Insights and Prior Exam Integration to its AI-Powered Breast SuiteJune 25 at 6:11 AM | markets.businessinsider.comDeepHealth Receives Two FDA Clearances Enabling it to Add Cardiovascular Insights and Prior Exam Integration to its AI-Powered Breast SuiteJune 25 at 6:00 AM | globenewswire.comRadNet, Inc. (NASDAQ:RDNT) Given Average Rating of "Moderate Buy" by BrokeragesJune 25 at 2:12 AM | americanbankingnews.comRadNet (NASDAQ:RDNT) Director David Swartz Sells 2,699 Shares of StockJune 23, 2026 | americanbankingnews.comRadNet (NASDAQ:RDNT) Director Sells 2,699 SharesJune 23, 2026 | insidertrades.comRadNet (NASDAQ:RDNT) CEO Sells $276,022.50 in StockJune 21, 2026 | americanbankingnews.comRadNet (NASDAQ:RDNT) CEO Cornelis Wesdorp Sells 4,750 SharesJune 19, 2026 | insidertrades.comWhy RadNet (RDNT) stock is down todayJune 17, 2026 | msn.comRadNet’s AI Reporting Pro And New Loan Put Focus On ValuationJune 13, 2026 | finance.yahoo.comIs It Too Late to Buy RadNet Inc (RDNT) After 3.5% Rally? GF Value Says UndervaluedJune 10, 2026 | gurufocus.comRadNet Secures $250 Million Incremental Term Loan to Fund Strategic Growth Opportunities and Reduces the Interest Rates on its Credit Facility by 0.25%June 10, 2026 | globenewswire.comDeepHealth, Inc. Launches Reporting Pro: An AI-Powered Solution to Revolutionize Radiology ReportingJune 10, 2026 | quiverquant.comQDeepHealth Launches Reporting Pro, Bringing AI Automation to Radiology ReportingJune 10, 2026 | globenewswire.comRadNet (RDNT): Buy, sell, or hold post Q1 earnings?June 8, 2026 | msn.comTesting & diagnostics services stocks Q1 results: Benchmarking RadNet (NASDAQ:RDNT)June 5, 2026 | msn.comAlpha Wave Global Reduces RadNet Stake, According to Recent SEC FilingJune 4, 2026 | aol.comAIs RadNet’s New US$200 Million Term Loan Reshaping the Investment Case for RDNT?June 4, 2026 | finance.yahoo.comRadNet Stockholders Approve All Proposals at 2026 MeetingJune 4, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRDNT, PSNL, and CSTL Company DescriptionsCastle Biosciences NASDAQ:CSTL$24.30 +1.39 (+6.07%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$24.26 -0.05 (-0.19%) As of 06/26/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.Personalis NASDAQ:PSNL$13.02 +0.43 (+3.42%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$12.70 -0.32 (-2.46%) As of 06/26/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.RadNet NASDAQ:RDNT$60.74 +0.73 (+1.22%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$60.72 -0.02 (-0.02%) As of 06/26/2026 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/22 - 06/26 Rocket Lab's NASA Win Tests Key Support After Sharp Pullback 3 ETFs Pairing Market-Beating Returns With High Dividend Yields BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone SpaceX Has Real Value—But These 3 Stocks Have Better Odds Right Now Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout 3 Stocks That Could Benefit as the Robotaxi Race Heats Up Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
